Procyon Biopharma Inc. is a Canadian biotechnology company actively engaged in the discovery and development of innovative therapeutic and diagnostic technologies in oncology and infectious diseases.
Ambrilia's product portfolio includes promising anti-HIV treatments, two new formulations of existing drugs developed with a patented technology, an anti-cancer therapeutic peptide, a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Contact details
To view this information, you must subscribe to PL Intelligence.
Head office
Ambrilia Biopharma
Ambrilia Biopharma Inc.
1000 chemin du Golf
Verdun
Quebec
H3E 1H4 Quebec
All rights reserved. Terms and Conditions | Contact us
